Replies to post #100232 on Biotech Values

[DewDiligence]

Another way of saying this is that although the various HCV drugs (nukes, non-nukes, PIs) target different parts of HCV, the mutations themselves are likely amenable to treatment from any class of HCV drugs, whether it be nukes, non-nukes, or PIs. Am I reading you right?

An entire class might be weak on a particular mutation, but any specific mutation is likely to be amenable to treatment from at least one of drugs in a given multi-class cocktail.